Benchmarking Study: Timelines for Vaccine Uptake and Implementation in Gavi countries


Timeline benchmarks are well-described for the product development process, but not for vaccine introduction and access.  These are useful  to accelerate vaccine access to countries and measure progress of new vaccine introductions, benchmarks against a standard.  Understanding bottlenecks and opportunities for acceleration during the process can also inform future product introductions.


The Benchmarking Study was a project conducted by Johns Hopkins Bloomberg School of Public Health International Vaccine Access Center (IVAC) and Applied Strategies/Strategic Decisions Group, designed to measure policy, implementation, and coverage milestones along the licensure-to-adoption pathway in 73 Gavi-eligible countries. The study collected dates and analyzed milestones across six  vaccine-preventable  diseases  (VPDs) and their corresponding prequalified vaccines (pentavalent vaccine, PCV, RVV, HPV vaccine, IPV, MenA vaccine).

IVAC led the country-level analyses, as well as developed a series of country case studies, which further explored the narrative around vaccine decision-making,  introduction, and implementation in Nigeria, Bangladesh, and The Gambia.


 There is no common pathway to introduction amongst the vaccines studied, but reaching certain milestones early in the process is important to introduction timelines.  Bottlenecks also varied, but ensuring that the product is appropriate for target countries can accelerate time to introduction and uptake. Additional results forthcoming – a manuscript describing the study’s quantitative findings is being prepared for submission. A manuscript detailing the successes of Bangladesh’s immunization program is currently being developed.